C. Cervino, R. Pasquali and U. Pagotto Pages 21 - 30 ( 10 )
Recent findings in animals and in humans have shown that cannabinoid type 1 receptor antagonists are suitable to become the most promising validated class of drugs to tackle obesity and related disorders. This mini-review will provide a concise and updated revision of the state of art on this topic.
Endocannabinoid, cannabinoid type 1 receptor, cannabinoid type 1 receptor antagonist, rimonabant, metabolic syndrome
Endocrinology Unit and C.R.B.A, Dept. of Internal Medicine and Gastroenterology, S. Orsola-Malpighi Hospital, Via Massarenti, 9, 40138 Bologna, Italy.